

AD \_\_\_\_\_

GRANT NO: DAMD17-94-J-4464

TITLE: Construction and characterization of human mammary epithelial cell lines containing mutations in p53 or BRCA1 genes.

PRINCIPAL INVESTIGATOR: Dr. Raymond L. White

CONTRACTING ORGANIZATION: University of Utah  
Salt Lake City, Utah 84112

REPORT DATE: 26 July 1995

19960103 193

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 3

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE 26 July 1995		3. REPORT TYPE AND DATES COVERED Annual 22 Sep 94 - 21 Sep 95	
4. TITLE AND SUBTITLE Construction and characterization of human mammary epithelial cell lines containing mutations in p53 or BRCA1 genes.				5. FUNDING NUMBERS DAMD17-94-J-4464	
6. AUTHOR(S) Dr. Raymond L. White					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Utah Salt Lake City, Utah 84112				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES					
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release, distribution unlimited				12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) To study the effects of inactivating mutations in the p53 and BRCA1 genes early in the breast cancer pathway, we will develop genetically defined human mammary epithelial cell (HMEC) lines by introducing heterozygous and homozygous mutations of each gene using homologous recombination. Additionally, we will construct HMEC lines deficient in p53 protein by expressing the E6 gene of human papillomavirus type 16 (HPV16), which increases the rate of degradation of the p53 protein. The consequences of these genetic changes for cell metabolism will be discovered through controlled in vitro comparisons between genetically altered derivatives and their isogenic parent cells. One level of comparison will involve observations of their growth properties, expression of certain cell lineage markers (e.g. keratins, integrins), morphology and behavior. At another level, we will take a global approach to the discovery of metabolic changes associated with genetic alterations in early tumorigenesis by constructing subtraction cDNA libraries and by differential display to reveal changes in mRNA transcription that are associated with loss of activity of each of these genes. Clones showing differential expression will be sequenced in our Sequence Core Facility at the University of Utah to reveal genes potentially critical in growth control, by reference to databanks.					
14. SUBJECT TERMS BRCA				15. NUMBER OF PAGES 12	
				16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited		

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

X Where copyrighted material is quoted, permission has been obtained to use such material.

X Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

X Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

X In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

X In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

X In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

*Ray White*

PI - Signature

*7/26/95*

Date

## Table of contents

1.	Front Cover .....	1
2.	Report Documentation Page .....	2
3.	Foreword .....	3
4.	Table Of Contents .....	4
5.	Introduction .....	5
6.	Body .....	5-9
7.	Conclusions .....	9
8.	References .....	9-12
9.	Appendix .....	12
	List of Salaried Personnel.....	12

Accession For	
NTIS CRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution /	
Availability Codes	
Dist	Avail and/or Special
A-1	

## (5) INTRODUCTION

Characterization of the early events in the development of breast cancer is expected to lead to a better understanding of transformation of normal cells to malignancy and may lead to new approaches for the detection of precancerous lesions and new treatment methods. Since germline mutations in two tumor suppressor genes, *p53* and *BRCA1*, are associated with inherited predisposition to breast cancer<sup>(1-5)</sup>, and losses of heterozygosity (LOH) on 17p and 17q occur frequently in sporadic breast tumors<sup>(6,7)</sup>, alterations in the *p53* (17p) and *BRCA1* (17q21) genes represent some of the earliest genetic changes known to occur in the development of breast cancer.

To study the effects of inactivating mutations in the *p53* and *BRCA1* genes early in the breast cancer pathway, we will develop genetically defined human mammary epithelial cell (HMEC) lines by introducing heterozygous and homozygous mutations of each gene using homologous recombination<sup>(8,9)</sup>. Additionally, we will construct HMEC lines deficient in *p53* protein by expressing the E6 gene of human papillomavirus type 16 (HPV16), which increases the rate of degradation of the *p53* protein<sup>(10-12)</sup>. The consequences of these genetic changes for cell metabolism will be discovered through controlled *in vitro* comparisons between genetically altered derivatives and their isogenic parent cells. One level of comparison will involve observations of their growth properties, expression of certain cell lineage markers (e.g. keratins, integrins), morphology and behavior. At another level, we will take a global approach to the discovery of metabolic changes associated with genetic alterations in early tumorigenesis by constructing subtraction cDNA libraries<sup>(13)</sup> and by differential display<sup>(14)</sup> to reveal changes in mRNA transcription that are associated with loss of activity of each of these genes. Clones showing differential expression will be sequenced in our Sequence Core Facility at the University of Utah to reveal genes potentially critical in growth control, by reference to databanks.

## (6) BODY

The following progress was made during the first year of the funded project (July 1, 1994 to June 30, 1995).

### **Culture of human mammary epithelial cells (HMEC) *in vitro***

Most breast cancers arise from epithelial cells of the mammary gland. Two types of epithelial cells are most common in the mammary gland: a continuous layer of glandular cells (luminal cells) lines the duct, whereas a discontinuous layer of cells near the basement membrane (basal cells) shares certain features of myoepithelial cells<sup>(15)</sup>. Intermediate phenotypes have also been observed<sup>(15)</sup>. Basal cells predominantly express 5 types of keratins (K), K5, K6, K7, K14, and K17, whereas luminal cells predominantly express 3 types, K8, K18, and K19<sup>(15-17)</sup>. Cancer cells in the breast produce mainly K8, K18, and K19<sup>(16)</sup>. Media are available to culture HMEC *in vitro* <sup>(17-20)</sup>. However, we have found that these media support only limited and slow growth of HMEC when the cells are plated on conventional plastic surfaces. We have recently developed a new system of co-culturing HMEC with fibroblasts, a strategy which seems to support better growth of HMEC of both luminal and basal origin (manuscript in preparation). Briefly, HMEC are maintained in DFCI-1<sup>(19)</sup> or MCDB 170<sup>(18)</sup> medium on a separate collagen-coated membrane insert arranged over fibroblasts. Using this co-culture system, we have established more than 40 primary HMEC cultures from reduction-mastectomy and breast-biopsy specimens.

### **Culture of HMEC from women who are known carriers of tumor suppressor gene mutations**

Breast biopsies from women who are members of high-risk breast cancer families are being made available to us through interested clinicians at the University of Utah. We have established several primary HMEC cultures from biopsy specimens taken from women who carry abnormal alleles of the *BRCA1*, *APC*, and *NFI*


genes. Additionally, we are to receive biopsy specimens from women who carry constitutional mutations in the *p53* gene (Li-Fraumeni syndrome) within 6 months.

These cultures will become important and convenient resources for constructing homozygously mutant HMEC lines, since they already carry one mutated allele.

### ***p53* gene knock-out by homologous recombination**

We will create *p53* knock-outs via homologous recombination in HMEC. Using the *p53*-containing cosmid clone that was isolated in our laboratory and the replacement vector pKT2<sup>(8)</sup>, we have constructed a *p53* replacement vector which contains three essential components: a positive selectable marker (neo), a negative selectable marker (HSV-tk), and 6 kb each of genomic DNA sequence from both the 5' and 3' regions of the *p53* gene, as shown in Figure 1. The positive selectable marker carries a neomycin-resistance gene under the control of human cytomegalovirus promoter. Upon homologous recombination, XbaI/BamHI genomic DNA containing the translation-initiation codon in exon 2 is replaced by the positive selectable marker. Cells that have incorporated the negative selectable marker (HSV-tk) through random integration will be counter-selected by gancyclovir<sup>(8)</sup>. This replacement vector, linearized by digestion with a single restriction enzyme, has been transfected into HMEC with DOTAP liposomal transfection reagent (Boehringer Mannheim). Cells have been selected with medium containing gancyclovir and G418, and we are now in the process of screening for successful integration of vector.

Figure 1



It is essential to develop a derivative line with homozygous mutation. One approach involves sequential targeting by two separate constructs using two different selectable markers (e.g. neomycin and hygromycin)<sup>(21)</sup>. Another approach would be to select for homozygous cells spontaneously produced from heterozygous cells by a variety of mechanisms including gene conversion and chromosomal loss followed by chromosomal duplication. Investigations with other systems have shown that, if the primary integration can be selected with relatively low levels of G418 (100-500mg/ml), cells that have undergone reduction to homozygosity can be selected with high levels of G418 (1-2mg/ml)<sup>(22)</sup>. Fortunately, HMEC are highly sensitive to G418, being effectively killed by 50mg/ml.

In addition to normal HMEC, we intend to use HMEC that already carry constitutional mutations in the *p53* gene (Li-Fraumeni syndrome), where only a single additional disruption is required, when those cells become available.

### ***BRCA1* gene knock-out by homologous recombination**

From the collection of overlapping P1 clones which were originally isolated in our laboratory from the *BRCA1* locus over the past two years<sup>(23)</sup>, we have identified two P1 clones, 63B3 and 84F2, in which exons 2 to 18 of the *BRCA1* gene are represented. Using these clones as resources for target DNA, we are constructing a *BRCA1* replacement vector similar to the one described above.

### **Ki-ras gene knock-out by homologous recombination**

We have obtained a vector for replacement of the Ki-ras gene which others have used successfully to disrupt the Ki-ras gene in human colon-cancer cell lines<sup>(24)</sup>. This construct will serve as a control for our series of homologous recombination experiments.

### **Retrovirus-mediated gene transfer**

The highly efficient retrovirus-mediated gene transfer system<sup>(25)</sup> became available in our laboratory during the past year. This system consists of ecotropic and amphotropic packaging cells and retrovirus vectors that contain varieties of promoters and drug selection markers<sup>(25,26)</sup>. Using this system, we have successfully introduced various genes into HMEC, including HPV16 E6 and E7<sup>(27)</sup>.

### **Immortalization of HMEC by HPV16 E6 and/or E7 and dominant inactivation of *p53***

For several years, specific interactions between transforming genes of DNA tumor viruses and the cellular regulatory proteins encoded by the *p53* and *RB* genes have been thought to form an important component of transformation by these viruses. It has been found that the DNA virus HPV16, implicated in cervical cancer, divides these interactions between two genes<sup>(28)</sup>: the E6 protein increases the rate of degradation of the *p53* protein through the ubiquitin pathway<sup>(10)</sup>, leading to undetectable levels in transfected HMEC lines<sup>(11,12)</sup>, and the E7 protein apparently binds the *RB* protein. We have successfully immortalized HMEC either by HPV16 E6 alone, E7 alone, or E6 and E7 together *via* retrovirus-mediated gene transfer<sup>(27)</sup>. Biochemical analysis has shown an expected loss of *p53* protein in both E6- and E6+E7- immortalized HMEC, but not in E7-immortalized HMEC (data not shown). Immunohistochemical staining of keratins has demonstrated that the majority of E6- immortalized cells exhibit the character of basal cells (K14+, K19-), whereas E7- or E6+E7- immortalized cells exhibit characteristics of luminal (K14-, K19+), basal (K14-, K19+), and mixed (K14+, K19+) cellular origins (data not shown). Recently, Wazer et al.<sup>(29)</sup> reported a similar observation, and they discussed the possibility of different susceptibilities to viral oncogenes among breast epithelial cell subtypes.

These observations are particularly useful for this project because immortalization may be necessary to support construction of HMEC with targeted tumor suppressor genes by homologous recombination. By conditionally expressing these viral genes, we will be able to determine whether immortalization has been achieved by the genetic alterations we are creating.

### **New strategies for conditional immortalization of HMEC**

As described above, although adequate doublings are available with primary HMEC culture for the selection of single-step heterozygous derivatives, these cultures may not survive long enough for the construction and testing of multi-step derivatives. It would be useful to have a defined, conditional immortalized system.

We first tested the hypothesis that the tsA58 or U19tsa allele of SV40 large T antigen can conditionally immortalize HMEC. These temperature-sensitive alleles of SV40 large T antigen have been used as conditionally immortalizing tools in several cell strains and in transgenic mice<sup>(30)</sup>. However, in our experience both temperature- sensitive constructs have failed to immortalize HMEC at their permissive temperature, although the wild-type SV40 large T antigen has been reported as an immortalizing tool in HMEC<sup>(17)</sup>.

The tetracycline-responsive promoter system developed by Gossen and Bujard<sup>(31)</sup> is in widespread use in many laboratories. In their system, a gene of interest is cloned downstream of the minimal human cytomegalovirus (HCMV) immediate early (IE) promoter fused to seven copies of the *Tn*-10 tetracycline operator (tetO). Expression from this promoter can be tightly controlled in stable cell lines that constitutively express a fusion protein termed tetracycline-controlled transactivator (tTA). The tTA consists of the tetracycline repressor combined with the C-terminal transcriptional transactivation domain of VP6 of herpes

simplex virus. Binding of the tTA cannot occur in the presence of tetracycline, and promoters containing tetO sequences are virtually silent in tTA-expressing HeLa cells. However, following removal of tetracycline, activity of the promoter is induced by up to 5 orders of magnitude. Although this original system has widespread utility, it is not functional in all cell types because the background activity of the tetO/HCMV IE promoter varies significantly in certain cell lines<sup>(32)</sup>. To examine whether this system would be applicable in our HMEC, we first established stable HMEC lines constitutively expressing the tTA by infecting retrovirus containing tTA and a neomycin-resistance gene. Cells were selected in medium containing 50mg/ml of G418, and resistant colonies were amplified as sister cell lines. Two sister lines, HMEC-tTA-1 and HMEC-tTA-2, were transiently transfected with pUHC13-3 plasmid containing the luciferase gene downstream to the tetO/HCMV IE promoter<sup>(31)</sup> with DOTAP liposomal transfection reagent (Boehringer Mannheim). Transfected cells were cultured for 48 h in the presence or absence of 1mg/ml tetracycline and assayed for luciferase activity. Results from duplicate experiments (Table 1) showed 1) low basal activity of the luciferase in the presence of tetracycline, and 2) up to 160-fold induction of the luciferase activity in the absence of tetracycline, indicating this conditional expression system is applicable in our HMEC lines.

Table 1  
average luciferase activity

HMEC-tTA-1	DNA (-)	52
	Tet (+)	67
	Tet (-)	2432
HMEC-tTA-2	DNA (-)	108
	Tet (+)	187
	Tet (-)	9760

We are now constructing plasmids similar to pUHC13-3 which will contain the HPV16 E6 and/or E7 genes in place of the luciferase gene, and a drug-selection marker (hygro) to select for stable clones. These plasmids will be transfected into HMEC constitutively expressing the tTA and cells will be selected in medium containing 20mg/ml of hygromycin. Stable lines that result will be tested for conditional immortalization as well as conditional inactivation of the *p53* protein.

In addition to the tetracycline system, we are also testing another inducible system, sheep metallothionein promoter. This promoter differs from that of mouse or human in that it does not contain a recognized basal level expression sequence motif; also, it may be unresponsive to glucocorticoids present in HMEC culture media<sup>(33,34)</sup>. This system has been used successfully to induce transformation of rat a fibroblast cell line by conditionally expressing v-myc oncogene<sup>(34)</sup>.

## Differential Display

The differential display technique originally described by Liang and Pardee<sup>(14)</sup> has been applied in several projects in our laboratory with moderate success over the past two years, using the DNA oligonucleotide primers and conditions originally described. Recently, several groups reported significant improvements involving choice of DNA oligonucleotide primers, PCR conditions, and non-radioactive detection systems. Many of these improvements have been incorporated and tested in our laboratory with very promising results. The differences are currently being verified by two independent means; firstly, repeated experiments, where RNAs from different harvests of cells serve as templates for the 1<sup>st</sup>-strand cDNA synthesis, are being performed to reproduce the original observation. Secondly, following the recovery and reamplification of RT-PCR products from the gels, these products are tested either by Northern blotting or by quantitative RT-PCR to confirm differences in expression level.



## (7) CONCLUSIONS

During the past year, the first year of our currently funded grant, we have established a series of primary HMEC cultures from normal individuals and from carriers of various tumor suppressor mutations, using our newly developed co-culture system. Homologous recombination experiments are in progress; one of the targeting vectors has been constructed and introduced, and candidate targeted HMEC clones are now in analysis. immortalization of HMEC was achieved by introducing HPV16 E6/E7 *via* retrovirus-mediated gene transfer. We have shown promising results for a conditional expression system, which will be applied for the construction of a controlled system to conditionally immortalize HMEC. One of the tools to characterize genetically defined HMEC, differential display, has been tested and is available.

However, in addition to the experiments outlined above, we think that the following experiments are also necessary.

A) Recently, Thompson et al.<sup>(35)</sup> reported that when *BRCA1* was down-regulated following addition of a *BRCA1* antisense oligonucleotide, they observed accelerated growth of both normal and malignant breast epithelial cells, which seemed to correspond to suppression of *BRCA1* expression. Thompson's group did not see this effect in non-mammary epithelial cells. If we can confirm their observation in our culture system by growing cells in the presence and absence of the same antisense oligonucleotide, these cells will also be characterized.

B) In parallel with our experiments involving homologous recombination and conditional expression of HPV16 E6/E7, we will screen HMEC lines established from women already carrying *p53* or *BRCA1* mutations for the spontaneous loss of the normal allele of each of these genes. Several human cell lines have been shown to produce homozygous loci from originally heterozygous sites at a low frequency, although the mechanism is not defined<sup>(36)</sup>. A recent study indicated that HMEC lines established from a Li-Fraumeni patient showed a high frequency of spontaneous immortalization when the wild-type *p53* allele was inactivated<sup>(37)</sup>, suggesting that once HMEC cultures are established it will not be difficult to obtain homozygosity for mutant alleles. Clones that have undergone reduction to homozygosity will be detected by means of semi-automated, PCR-based fluorescence genotyping at our Genotyping Core Facility at the University of Utah.

C) As an alternative means of inactivating *p53* in HMEC, we will develop cell lines in which the *p53* protein is rendered non-functional by: 1) over-expressing the *mdm-2* oncogene<sup>(38)</sup>, the protein product of which is known to bind and inactivate *p53*; and by 2) over-expressing variants of the *p53* protein which are believed to inhibit the normal function of *p53* by a dominant-negative mechanism<sup>(38)</sup>. These experiments are important because, since *p53* is not the only protein to bind to HPV16 E6, degradation of *p53* may not be the only reason for immortalization and subsequent changes caused by HPV16 E6.

The resulting genetically defined HMEC lines will be important resources for studying some of the early genetic changes that are thought to occur in the development of breast cancer. Characterization of the consequences of such changes will be highly relevant to the understanding of tumor progression and may lead to new applications for early detection, prevention, and treatment of breast cancer.

## (8) REFERENCES

1. Malkin ZD, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, and Friend SH (1990). Germ line *p53* mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science* 250: 1233-1238.
2. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, and King M-C (1990). Linkage of early-onset familial breast cancer to chromosome 17q21. *Science* 250: 1684-1689.

3. Hollstein M, Sidransky D, Vogelstein B, and Harris CC (1991). p53 mutations in human cancers. *Science* 253: 49-53.
4. Miki Y, et al. (1994) A strong candidate gene for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 266:66-71.
5. Futreal PA, et al. (1994). BRCA1 mutations on primary breast and ovarian carcinomas. *Science* 266:120-122.
6. Callahan R, Cropp CS, Merlo GR, Liscia DS, Cappa APM, and Lidereau R (1992). Somatic mutations and human breast cancer: a status report. *Cancer [Suppl]* 69: 1582-1588.
7. Cropp CS, Nevanlinna HA, Pyrhonen S, Stenman U-H, Salmikangas P, Albertsen H, White R, and Callahan R (1994) Evidence for involvement of BRCA1 in sporadic carcinomas. *Cancer Res.* 54:2548-2551.
8. Mansour SL, Thomas KR, and Capecchi MR (1988). Disruption of the proto-oncogene *int-2* in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. *Nature* 336:348-352.
9. Capecchi MR (1994). Targeted gene replacement. *Sci. Am.* 270:54-61.
10. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. *Cell* 63:1129-1136.
11. Band V, DeCaprio JA, Delmolino L, Kulesa V, and Sager R (1991). Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells. *J. Virol.* 65:6671-6676.
12. Band V, Dalal S, Delmolino L, and Androphy EJ (1993). Enhanced degradation of p53 protein in HPV-6 and BPV-1 E6-immortalized human mammary epithelial cells. *EMBO J.* 12:1847-1852.
13. Houge G (1993). Simplified construction of a subtracted cDNA library using asymmetric PCR. In: *PCR methods and Applications*, Vol. 2. New York: Cold Spring Harbor Laboratory, pp. 204-209.
14. Liang P and Pardee A (1992). Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. *Science* 257:967-971.
15. Taylor-Papadimitriou J and Lane EB (1987). in *The Mammary Gland: Development, Regulation and Function*, eds. Neville MC and Daniel CW. (Plenum, New York), Vol. 6, pp. 181-215.
16. Trask DK, Band V, Zajchowski DA, Yaswen P, Suh T, and Sager R (1990). Keratins as markers that distinguish normal and tumor-derived mammary epithelial cells. *Proc. Natl. Acad. Sci. USA* 87:2319-2323.
17. Bartek J, Bartkova J, Kyprianou N, Lalani E-N, Staskova Z, Shearer M, Chang S, and Taylor-Papadimitriou J (1991). Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with a recombinant retrovirus. *Proc. Natl. Acad. Sci. USA* 88:3520-3524.
18. Hammond SL, Ham RG, and Stampfer MR (1984). Serum-free growth of human mammary epithelial cells: Rapid clonal growth in defined medium and extended serial passage with pituitary extract. *Proc. Natl. Acad. Sci. USA* 81:5435-5439.
19. Band V and Sager R (1989). Distinctive traits of normal and tumor- derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types. *Proc. Natl. Acad. Sci. USA* 86:1249-1253.

20. Ethier SP, Mahacek ML, Gullick WJ, Frank TS, and Weber BL (1993). Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. *Cancer Res.* 53:627-635.
21. Cruz A, Coburn CM, and Beverley SM (1991). Double targeted gene replacement for creating null mutants. *Proc. Natl. Acad. Sci. USA* 88:7170-7174.
22. Mortensen RM, Conner DA, Chao S, Geisterfer-Lowrance AAT, and Seidman JG (1992). Production of homozygous mutant ES cells with a single targeting construct. *Mol. Cell. Biol.* 12:2391-2395.
23. Albertsen HA, Smith SA, Mazoyer S, Fujimoto E, Stevens J, Williams B, Rodriguez P, Cropp CS, Slijepcevic P, Carlson M, Robertson M, Bradley P, Lawrence E, Sheng ZM, Hoopes R, Sternberg N, Brothman A, Callahan R, Ponder BAJ, and White R (1994). A physical map and candidate genes in the BRCA1 region. *Nature Genetics* 7:472-479.
24. Shirasawa S, Furuse M, Yokoyama N, and Sasazuki T (1993). Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. *Science* 260:85-88.
25. Miller AD, Miller DG, Garcia JV, and Lynch CM (1993). Use of retroviral vectors for gene transfer and expression. *Methods in Enzymology* 217: 581-599.
26. Danos O and Mulligan RC (1988). Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. *Proc. Natl. Acad. Sci. USA* 85:6460-6464.
27. Halbert CL, Demers GW, and Galloway DA (1991). The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. *J. Virol.* 65:473-478.
28. Howley PM (1991). Role of the human papillomavirus in human cancer. *Cancer Res.* 51 [Suppl]:5019s-5020s.
29. Wazer DE, Liu XL, Chu Q, Gao Q, and Band V (1995). Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7. *Proc. Natl. Acad. Sci. USA* 92:3687-3691.
30. Whitehead RH, VanEeden PE, Noble MD, Ataliotis P, and Jat P (1993). Establishment of conditionally immortalized epithelial cell lines from both colon and intestine of adult H-2K<sup>b</sup>-tsA58 transgenic mice. *Proc. Natl. Acad. Sci. USA* 90:587-591.
31. Gossen M and Bujard H (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. *Proc. Natl. Acad. Sci. USA* 89:5547-5551.
32. Ackland-Berglund C and Leib DA (1995). Efficiency of tetracycline-controlled gene expression is influenced by cell types. *BioTechniques* 18:196-200.
33. Peterson MG and Mercer JFB (1986). Structure and regulation of the sheep metallothionein-Ia gene. *Eur. J. Biochem.* 160:579-585.
34. Bonham L, Kwok J, Chisholm O, and Symonds G (1991). Inducible transformation of fibroblasts using a metallothionein-v-myc gene construct. *Oncogene* 6:1073-1077.
35. Thompson ME, Jensen RA, Obermiller PS, Page DL, and Holt JT (1995). Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. *Nature Genetics* 9:444-450.

36. Groden J, Nakamura Y, and German J (1990). Molecular evidence that homologous recombination occurs in proliferating somatic cells. *Proc. Natl. Acad. Sci. USA* 87:4315-4319.
37. Shay JW, Tomlinson G, Piatyszek MA, and Gollahon LS (1995). Spontaneous *in vitro* immortalization of breast epithelial cells from a patient with Li-Fraumeni Syndrome. *Mol. Cell. Biol.* 15: 425-432.
38. Hoppe-Seyler F and Butz K (1993). Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. *J. Virol.* 67:3111-3117.

## (9) APPENDIX

List of salaried personnel:

<u>Name</u>	<u>Position</u>
Nori Matsunami	Research Associate
Ray White	P.I.
Joni Johnson	Postdoc
Leslie Jerominski	Research Associate